Recent advances in the discovery and development of topoisomerase inhibitors as antitumor agents
- 1 July 1997
- journal article
- review article
- Published by Wiley in Medicinal Research Reviews
- Vol. 17 (4), 367-425
- https://doi.org/10.1002/(sici)1098-1128(199707)17:4<367::aid-med3>3.0.co;2-u
Abstract
No abstract availableKeywords
This publication has 97 references indexed in Scilit:
- From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): Selectivity for topoisomerases I and II among acridine derivativesEuropean Journal Of Cancer, 1996
- Phase II study of amonafide in patients with recurrent gliomaJournal of Neuro-Oncology, 1995
- Amonafide as first-line chemotherapy for metastatic breast cancerEuropean Journal Of Cancer, 1994
- DNA damage and topoisomerase II inhibition induced by a benzopsoralen derivativeMutation Research, 1994
- Streptonigrin-Induced Topoisomerase II Sites Exhibit Base Preferences in the Middle of the Enzyme StaggerBiochemical and Biophysical Research Communications, 1994
- Phase II study of pirarubicin combined with cisplatin in recurrent ovarian cancerZeitschrift für Krebsforschung und Klinische Onkologie, 1994
- Phase II study of pirarubicin (THP) in patients with cervical, endometrial and ovarian cancer: Study of the clinical screening group of the European Organization for Research and Treatment of Cancer (EORTC)European Journal Of Cancer, 1993
- Biochemical characterisation of elsamicin and other coumarin-related antitumour agents as potent inhibitors of human topoisomerase IIEuropean Journal Of Cancer, 1993
- Phase II trial of pirarubicin in epidermoid carcinoma of the head and neckEuropean Journal Of Cancer, 1992
- Alkaloids of Ochrosia elliptica Labill.1Journal of the American Chemical Society, 1959